The Galien Forum USA 2019

PANEL
3

Chair
Mikael Dolsten
Chief Scientific Officer & President,
Worldwide Research, Development & Medical
Pfizer

Panelists
Karin Briner
Vice President & Head, Global Discovery Chemistry
Novartis Institutes for BioMedical Research

Alessio Ciulli
Professor of Chemical and Structural Biology, School of Life Sciences
University of Dundee

Craig Crews
Founder & Chief Scientific Officer
Arvinas

Jennifer Petter
Chief Scientific Officer
Arrakis

Michael Ringel
Senior Partner & Managing Director
BCG

Panel Intro

"Drugging the undruggable" with novel approaches to small molecule design


Chair
Mikael Dolsten
Chief Scientific Officer and President, Worldwide Research, Development & Medical
Pfizer

Mikael Dolsten focuses on advancing Pfizer’s scientific leadership in small-molecule medicines, biotherapeutics and vaccines. He is a member of the Executive Leadership Team and the company’s Portfolio Strategy and Investment Committee, which governs major pipeline investments and strategic end-to-end R&D priorities.

Mikael leads the Worldwide Research, Development and Medical (WRDM) organization at Pfizer, which is responsible for the development of all compounds through proof of concept, and provides pharmaceutical sciences, safety and medical support to the entire R&D pipeline and all marketed products. The WRDM group contains all Pfizer research units, including Oncology, Internal Medicine, Inflammation & Immunology, Vaccines and Rare Disease, as well as the Centers for Therapeutic Innovation (CTI). Mikael also has worldwide responsibility for Pfizer’s groups in medical, safety and external R&D innovation, in addition to science-based teams in pharmaceutical sciences, drug safety R&D, and large and small molecule discovery and development.

Prior to joining Pfizer in 2009, Mikael was President of Wyeth Research, where he led scientists involved in all R&D/Medical activities across the US, Europe and Asia. Before that, Mikael served as EVP and Head of Worldwide Research for Boehringer Ingelheim from 2003-2008.

Mikaels and a fellow of the New York Academy of Medicine, and serves on the Science and   Mikael advised the Obama Administration on regulatory and drug development issues as well as Vice President Biden’s Cancer Moonshot Initiative to accelerate cancer research. Through 2019, Dr. Dolsten was a council member of the Government-University-Industry Research Roundtable (GUIRR).

Mikael is a named inventor on several patents and has published approximately 150 articles in international journals, with contributions in molecular cell biology, immunology and oncology.


Karin Briner
Vice President & Head Global Discovery Chemistry
Novartis Institutes for BioMedical Research


Alessio Ciulli
Professor of Chemical and Structural Biology, School of Life Sciences
University of Dundee

Alessio’s research focuses on the development and mechanistic understanding of small molecules inducing protein degradation and modulating protein-protein interactions. His group has made significant contributions to selective chemical intervention on important biological and therapeutic systems. In collaboration with the Crews Lab, they pioneered the structure-guided design of VHL ligands, which helped to jump-start the PROTAC field and led to significant commercial impact across academia and biopharma worldwide. More recently, Alessio’s Lab has illuminated structural and mechanistic insights into PROTAC’s molecular recognition and mode of action, including the first crystal structure of a PROTAC ternary complex.

After gaining an MSci (University of Florence) and PhD (University of Cambridge and Astex Pharmaceuticals), and pursuing postdoctoral research at Cambridge and a visiting fellowship at Yale University, Alessio began his independent academic career in 2009. His laboratory has been based at Dundee’s School of Life Sciences since 2013, where he currently holds the Personal Chair of Chemical and Structural Biology. In 2016, Alessio established a major collaboration on PROTAC drug discovery between Dundee and Boehringer Ingelheim. He is the Scientific Founder of Amphista Therapeutics, a Dundee spin off company focused on protein degradation platforms. He is a Fellow of the Royal Society of Chemistry.


Craig Crews
Founder & Chief Scientific Officer
Arvinas

Dr. Crews is the American Cancer Society Professor of Molecular, Cellular and Developmental Biology and holds joint appointments in the departments of Chemistry and Pharmacology at Yale University.  He graduated from the U. Virginia with a B.A. in Chemistry and received his Ph.D. from Harvard University in Biochemistry. Dr. Crews has a foothold in both the academic and biotech arenas; on the faculty at Yale since 1995, his laboratory pioneered the use of small molecules to control intracellular protein levels. His first company, Proteolix, developed the proteasome inhibitor, Kyprolis™ for the treatment of multiple myeloma.  His second venture, Arvinas, applies his lab’s PROTAC ‘induced protein degradation’ technology to drug development.  He has received numerous awards and honors, including the CURE Entrepreneur of the Year Award (2013), Ehrlich Award for Medicinal Chemistry (2014), Yale Cancer Center Translational Research Prize (2015), a NIH R35 Outstanding Investigator Award (2015), the AACR Award for Outstanding Achievement in Chemistry in Cancer Research (2017), the  Khorana Prize from the Royal Society of Chemistry ( 2018), the  Pierre Fabre Award for Therapeutic Innovation (2018), the Pharmacia-ASPET Award for Experimental Therapeutics (2019) and was named an American Cancer Society Professor in 2018.


Jennifer PetterJennifer Petter
Chief Scientific Officer
Arrakis

Dr. Petter is the Founder and CSO of Arrakis Therapeutics.  Previously she was Vice President of Chemistry at Celgene, Vice President of Drug Discovery at Avila Therapeutics, Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen, Section Head in Oncology Chemistry at Sandoz/Novartis, and Assistant Professor of Chemistry at the University of Pittsburgh.  Dr. Petter graduated from Dartmouth College with an AB in chemistry, earned her PhD in organic chemistry at Duke University with Ned Porter, and was a post-doctoral fellow in Ron Breslow’s group at Columbia University.  She has ushered multiple compounds into clinic trials for the treatment of cancer, cardiovascular disease, autoimmune disorders, and sepsis.


Michael Ringel webMichael Ringel
Senior Partner & Managing Director
BCG

Michael Ringel is a Managing Director and Senior Partner in BCG’s Boston office. He previously was BCG’s Global Topic Leader for Research & Product Development and is currently the Global Topic Leader for Innovation Analytics, covering a range of analytical tools applied to R&D and innovation.

Michael has worked for a number of biotech and pharmaceutical clients on R&D topics across strategy, operations, organization and advanced analytics. In addition to his client work, he is a frequent writer and speaker on R&D/innovation topics, with articles in Nature Reviews Drug Discovery, Drug Discovery Today and other academic journals, and a TED talk on external innovation.

Michael is also Strategic Advisor to Life Biosciences, a biotech company focused on revolutionary approaches to longevity and addressing age-related diseases.

Michael holds a B.A. summa cum laude in biology from Princeton, where he graduated #1 in the department, a Ph.D. in biology from Imperial College (NSF and Fulbright Fellowships awarded), and a J.D. cum laude from Harvard Law School.

He sits on the Board of The Nature Conservancy in Massachusetts, has three children, and loves travel and playing guitar.